Parkinson's Disease iPS Cell Line Research Consortium

Overview

  • Study type

    Observational
  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Scottsdale/Phoenix, Arizona: 09-003803
    • Jacksonville, Florida: 09-003803
    Sponsor Protocol Number: 09-003803

About this study

This study is being done to collect skin samples from people with and without neurodegenerative and vascular disorders including Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), stroke and many others. We will use these skin samples to make and bank (store) a group of cells (cell line) called inducible pluripotent stem (iPS) cells.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria: 

  • Willing and able to give informed consent
  • Male and females over the age of 18
  • Diagnosis of Parkinson's Disease (PD), other neurodegenerative conditions, and vascular disorders with genetic mutation or family members if needed to maintain blinded status to their mutation.
  • Patients with Parkinson's Disease (PD), other neurodegenerative disorders, and vascular disorders who do not have known family history.
  • Age/gender controls

Exclusion Criteria:

  • Patients that do not want to participate by either checking no on the contact letter or refusing over the phone. This will be recorded in the progeny system and patients will not be contacted again.
  • Allergy to study-related materials including lidocaine or iodine

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Zbigniew Wszolek, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Mark Pittelkow M.D.

(480)301-8000

pittelkow.mark@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Zbigniew Wszolek, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Audrey Strongosky

(904)953-6096

Strongosky.Audrey2@mayo.edu